BIN1 Isoform Biomarker for Cancer Detection and Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for early diagnosis and monitoring of cancer, particularly for metastasis and treatment efficacy, lack effective biomarkers to accurately detect cancer progression and respond to therapy changes.
Innovation Solution
The use of Bridging Integrator 1 (BIN1) isoforms, specifically 12a+ BIN1 isoforms, as biomarkers in blood samples to diagnose cancer, monitor progression, and assess treatment efficacy by measuring levels of Ca-1 and Ca-2 isoforms, with the aid of specific antibodies and assays to detect these isoforms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used for early diagnosis and monitoring of cancer, then general cancer detection is possible, but accurate detection of cancer progression and treatment efficacy is insufficient due to lack of effective biomarkers
Solution Approach 1:
The invention segments the BIN1 gene into multiple isoforms (12a+ BIN1, 12a-/13+ BIN1, etc.) with distinct expression patterns in cancer versus normal tissues. By measuring specific isoform ratios rather than total BIN1 expression, the method achieves precise cancer detection and monitoring capabilities.
Solution Approach 2:
The invention changes the measurement parameter from total BIN1 protein levels to specific isoform ratios (e.g., 12a+ BIN1/12a-/13+ BIN1). This parameter transformation enables accurate differentiation between cancer and normal states, and monitors treatment efficacy by tracking isoform ratio changes over time.
2Productivity
If traditional cancer monitoring methods are used, then general treatment tracking is possible, but effective monitoring of metastasis and treatment effects is lacking
Solution Approach 1:
The invention implements a feedback mechanism by repeatedly measuring BIN1 isoform ratios in blood samples before, during, and after cancer treatment. The changing isoform ratios provide real-time feedback on treatment efficacy, allowing clinicians to adjust therapy based on molecular response rather than waiting for anatomical changes.
Solution Approach 2:
The BIN1 isoform ratio measurement serves multiple functions: early cancer detection, monitoring disease progression, assessing treatment efficacy, and predicting metastasis. This single biomarker system replaces multiple separate monitoring approaches, improving efficiency while maintaining comprehensive information.
3Adaptability or versatility
If non-specific cancer markers are used, then general cancer screening is possible, but accurate risk stratification and therapy guidance is insufficient
Solution Approach 1:
The invention applies local quality by measuring specific BIN1 isoform expressions (12a+, 12a-/13+) that are locally upregulated in cancer tissues compared to normal tissues. This localized molecular signature provides precise risk stratification and guides personalized therapy selection based on the specific isoform pattern observed.
Data Source
AI summary
Provided are methods for screening a subject for cancer. The methods involve obtaining a blood sample from the subject and determining a level of Bridging Integrator 1 (BIN1) isoforms comprising exon 12a in the sample. Optionally, the method involves determining a level of 12a+/13− BIN isoform (comprising exon 12a but lacking exon 13) in the sample. An elevated level of 12a+(e.g., 12a+/13−) BIN1 isoforms in the blood sample indicates the subject has cancer. Also provided are methods for determining efficacy of a cancer therapy in a subject and methods of treating cancer. Isolated antibodies that selectively bind human 12a+ BIN1 are also provided as well as kits for determining 12a+/13− BIN1 isoforms.